

Frederick G Hayden

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1776320/publications.pdf>

Version: 2024-02-01

163
papers

35,278
citations

6254

80
h-index

6836

155
g-index

185
all docs

185
docs citations

185
times ranked

38148
citing authors

#	ARTICLE	IF	CITATIONS
1	Reducing Influenza Virus Transmission: The Potential Value of Antiviral Treatment. <i>Clinical Infectious Diseases</i> , 2022, 74, 532-540.	5.8	25
2	COVID-19, Influenza and RSV: Surveillance-informed prevention and treatment – Meeting report from an isirv-WHO virtual conference. <i>Antiviral Research</i> , 2022, 197, 105227.	4.1	19
3	Favipiravir Treatment of Uncomplicated Influenza in Adults: Results of Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Trials. <i>Journal of Infectious Diseases</i> , 2022, 226, 1790-1799.	4.0	16
4	Influenza Therapeutics in Clinical Practice – Challenges and Recent Advances. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2021, 11, a038463.	6.2	24
5	Surviving Sepsis Campaign Guidelines on the Management of Adults With Coronavirus Disease 2019 (COVID-19) in the ICU: First Update. <i>Critical Care Medicine</i> , 2021, 49, e219-e234.	0.9	289
6	Influenza polymerase inhibitor resistance: Assessment of the current state of the art - A report of the isirv Antiviral group. <i>Antiviral Research</i> , 2021, 194, 105158.	4.1	24
7	Baloxavir Treatment in Adolescents With Acute Influenza: Subgroup Analysis From the CAPSTONE-1 Trial. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2021, 10, 477-484.	1.3	6
8	Treatment-Emergent Influenza Variant Viruses With Reduced Baloxavir Susceptibility: Impact on Clinical and Virologic Outcomes in Uncomplicated Influenza. <i>Journal of Infectious Diseases</i> , 2020, 221, 346-355.	4.0	104
9	Baloxavir Marboxil in Japanese Pediatric Patients With Influenza: Safety and Clinical and Virologic Outcomes. <i>Clinical Infectious Diseases</i> , 2020, 71, 971-981.	5.8	99
10	Treatment of Middle East respiratory syndrome with a combination of lopinavir/ritonavir and interferon- β (MIRACLE trial): statistical analysis plan for a recursive two-stage group sequential randomized controlled trial. <i>Trials</i> , 2020, 21, 8.	1.6	108
11	Comparative Effectiveness of Combined Favipiravir and Oseltamivir Therapy Versus Oseltamivir Monotherapy in Critically Ill Patients With Influenza Virus Infection. <i>Journal of Infectious Diseases</i> , 2020, 221, 1688-1698.	4.0	103
12	Antiviral monotherapy for hospitalised patients with COVID-19 is not enough. <i>Lancet</i> , The, 2020, 396, 1310-1311.	13.7	16
13	Phase 2a, open-label, dose-escalating, multi-center pharmacokinetic study of favipiravir (T-705) in combination with oseltamivir in patients with severe influenza. <i>EBioMedicine</i> , 2020, 62, 103125.	6.1	36
14	Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 1204-1214.	9.1	134
15	Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19). <i>Intensive Care Medicine</i> , 2020, 46, 854-887.	8.2	1,536
16	Baloxavir Marboxil for Prophylaxis against Influenza in Household Contacts. <i>New England Journal of Medicine</i> , 2020, 383, 309-320.	27.0	93
17	Use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: a retrospective analysis. <i>Frontiers of Medicine</i> , 2020, 14, 601-612.	3.4	38
18	Critical care management of adults with community-acquired severe respiratory viral infection. <i>Intensive Care Medicine</i> , 2020, 46, 315-328.	8.2	172

#	ARTICLE	IF	CITATIONS
19	A novel coronavirus outbreak of global health concern. <i>Lancet, The</i> , 2020, 395, 470-473.	13.7	5,656
20	Comment to: Baloxavir efficacy in North American Adults. <i>European Journal of Internal Medicine</i> , 2020, 72, 99-101.	2.2	0
21	Respiratory Syncytial Virus Antivirals: Problems and Progress. <i>Journal of Infectious Diseases</i> , 2020, 222, 1417-1421.	4.0	19
22	Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. <i>Lancet, The</i> , 2020, 395, 1569-1578.	13.7	2,875
23	Surviving Sepsis Campaign: Guidelines on the Management of Critically Ill Adults with Coronavirus Disease 2019 (COVID-19). <i>Critical Care Medicine</i> , 2020, 48, e440-e469.	0.9	816
24	Evaluation of the efficacy and safety of intravenous remdesivir in adult patients with severe COVID-19: study protocol for a phase 3 randomized, double-blind, placebo-controlled, multicentre trial. <i>Trials</i> , 2020, 21, 422.	1.6	59
25	Antivirals targeting the polymerase complex of influenza viruses. <i>Antiviral Research</i> , 2019, 169, 104545.	4.1	122
26	Noninvasive ventilation in critically ill patients with the Middle East respiratory syndrome. <i>Influenza and Other Respiratory Viruses</i> , 2019, 13, 382-390.	3.4	91
27	Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenzaa. <i>Clinical Infectious Diseases</i> , 2019, 68, 895-902.	5.8	251
28	Macrolides in critically ill patients with Middle East Respiratory Syndrome. <i>International Journal of Infectious Diseases</i> , 2019, 81, 184-190.	3.3	103
29	Influenza virus polymerase inhibitors in clinical development. <i>Current Opinion in Infectious Diseases</i> , 2019, 32, 176-186.	3.1	180
30	Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenzaa. <i>Clinical Infectious Diseases</i> , 2019, 68, e1-e47.	5.8	449
31	Corticosteroid Therapy for Critically Ill Patients with Middle East Respiratory Syndrome. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 197, 757-767.	5.6	911
32	1645. Exploring Clinical and Antiviral Efficacy of Baloxavir Marboxil in a Phase 3, Randomized, Double-Blind, Placebo- and Active-Controlled Study of Otherwise Healthy Adults/Adolescents in Seasonal Influenza: Impact on Regional Participants, Treatment Time and Influenza Type B Virus Infection (CAPSTONE-1 Study). <i>Open Forum Infectious Diseases</i> , 2018, 5, S48-S48.	0.9	2
33	LB16. Phase 3 Trial of Baloxavir Marboxil in High-Risk Influenza Patients (CAPSTONE-2 Study). <i>Open Forum Infectious Diseases</i> , 2018, 5, S764-S765.	0.9	27
34	Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents. <i>New England Journal of Medicine</i> , 2018, 379, 913-923.	27.0	629
35	Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon- β 1b (MIRACLE trial): study protocol for a randomized controlled trial. <i>Trials</i> , 2018, 19, 81.	1.6	221
36	Experimental Therapies for Ebola Virus Disease: What Have We Learned?. <i>Journal of Infectious Diseases</i> , 2017, 215, jiw496.	4.0	23

#	ARTICLE	IF	CITATIONS
37	Serotherapy for patients with severe influenza. <i>Lancet Respiratory Medicine</i> , 2017, 5, 462-464.	10.7	1
38	Critically Ill Patients With the Middle East Respiratory Syndrome: A Multicenter Retrospective Cohort Study. <i>Critical Care Medicine</i> , 2017, 45, 1683-1695.	0.9	139
39	Antiviral Agents Against Respiratory Viruses. , 2017, , 1318-1326.e2.		11
40	Colorado Tick Fever and Other Arthropod Borne Reoviridae. , 2016, , 841-852.		1
41	Respiratory Syncytial Virus, Human Metapneumovirus, and Parainfluenza Viruses. , 2016, , 873-902.		1
42	Influenza Virus. , 2016, , 1009-1058.		5
43	Rotaviruses. , 2016, , 853-872.		0
44	The search for therapeutic options for Middle East Respiratory Syndrome (MERS). <i>Journal of Infection and Public Health</i> , 2016, 9, 213-215.	4.1	2
45	Infectious Diseases Society of America and Gain-of-Function Experiments With Pathogens Having Pandemic Potential. <i>Journal of Infectious Diseases</i> , 2016, 213, 1359-1361.	4.0	5
46	Anti-infective immunoadhesins from plants. <i>Plant Biotechnology Journal</i> , 2015, 13, 1078-1093.	8.3	18
47	Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: a study protocol. <i>SpringerPlus</i> , 2015, 4, 709.	1.2	163
48	Design, recruitment, and microbiological considerations in human challenge studies. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 840-851.	9.1	107
49	Overview of the 3rd isirv Antiviral Group Conference advances in clinical management. <i>Influenza and Other Respiratory Viruses</i> , 2015, 9, 20-31.	3.4	17
50	Editorial Commentary: Host and Viral Factors in Emergent Influenza Virus Infections. <i>Clinical Infectious Diseases</i> , 2014, 58, 1104-1106.	5.8	7
51	Emerging novel and antimicrobial-resistant respiratory tract infections: new drug development and therapeutic options. <i>Lancet Infectious Diseases</i> , The, 2014, 14, 1136-1149.	9.1	91
52	Antiviral combinations for severe influenza. <i>Lancet Infectious Diseases</i> , The, 2014, 14, 1259-1270.	9.1	159
53	Towards improving clinical management of Middle East respiratory syndrome coronavirus infection. <i>Lancet Infectious Diseases</i> , The, 2014, 14, 544-546.	9.1	30
54	Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus. <i>Journal of Infection</i> , 2013, 67, 606-616.	3.3	314

#	ARTICLE	IF	CITATIONS
55	Addressing the public health burden of respiratory viruses: the Battle against Respiratory Viruses (BRaVe) Initiative. <i>Future Virology</i> , 2013, 8, 953-968.	1.8	44
56	Therapy of H7N9 pneumonia: current perspectives. <i>Expert Review of Anti-Infective Therapy</i> , 2013, 11, 1123-1126.	4.4	9
57	Advances in antivirals for non-influenza respiratory virus infections. <i>Influenza and Other Respiratory Viruses</i> , 2013, 7, 36-43.	3.4	39
58	Newer influenza antivirals, biotherapeutics and combinations. <i>Influenza and Other Respiratory Viruses</i> , 2013, 7, 63-75.	3.4	60
59	Rhinovirus Genetics and Virulence. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012, 186, 818-820.	5.6	4
60	Combination Antiviral Therapy for Influenza: Predictions From Modeling of Human Infections. <i>Journal of Infectious Diseases</i> , 2012, 205, 1642-1645.	4.0	59
61	Antiviral resistance during the 2009 influenza A H1N1 pandemic: public health, laboratory, and clinical perspectives. <i>Lancet Infectious Diseases</i> , The, 2012, 12, 240-248.	9.1	186
62	Experimental human influenza: observations from studies of influenza antivirals. <i>Antiviral Therapy</i> , 2012, 17, 133-141.	1.0	29
63	Emerging Influenza Antiviral Resistance Threats. <i>Journal of Infectious Diseases</i> , 2011, 203, 6-10.	4.0	159
64	End Points for Testing Influenza Antiviral Treatments for Patients at High Risk of Severe and Life-Threatening Disease. <i>Journal of Infectious Diseases</i> , 2010, 201, 1654-1662.	4.0	65
65	Clinical Aspects of Pandemic 2009 Influenza A (H1N1) Virus Infection. <i>New England Journal of Medicine</i> , 2010, 362, 1708-1719.	27.0	1,003
66	Antiviral Drugs (Other than Antiretrovirals). , 2010, , 565-610.		8
67	Seasonal Influenza in Adults and Children—Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management: Clinical Practice Guidelines of the Infectious Diseases Society of America. <i>Clinical Infectious Diseases</i> , 2009, 48, 1003-1032.	5.8	604
68	Developing New Antiviral Agents for Influenza Treatment: What Does the Future Hold?. <i>Clinical Infectious Diseases</i> , 2009, 48, S3-S13.	5.8	239
69	Patient-oriented pandemic influenza research. <i>Lancet</i> , The, 2009, 373, 2085-2086.	13.7	13
70	Surveillance for neuraminidase-inhibitor-resistant influenza viruses in Japan, 1996–2007. <i>Antiviral Therapy</i> , 2009, 14, 751-762.	1.0	71
71	Antiviral Resistance in Influenza Viruses: Clinical and Epidemiological Aspects. , 2009, , 1011-1033.		3
72	Effects of dietary supplementation with conjugated linoleic acid on experimental human rhinovirus infection and illness. <i>Antiviral Therapy</i> , 2009, 14, 33-43.	1.0	17

#	ARTICLE	IF	CITATIONS
73	The Southeast Asian Influenza Clinical Research Network: Development and challenges for a new multilateral research endeavor. <i>Antiviral Research</i> , 2008, 78, 64-68.	4.1	17
74	Update on Avian Influenza A (H5N1) Virus Infection in Humans. <i>New England Journal of Medicine</i> , 2008, 358, 261-273.	27.0	814
75	Antivirals for Influenza: Novel Agents and Approaches. , 2008, , 179-192.		1
76	John F. Enders Lecture 2006: Antivirals for Influenza. <i>Journal of Infectious Diseases</i> , 2007, 196, 181-190.	4.0	58
77	WHO Rapid Advice Guidelines for pharmacological management of sporadic human infection with avian influenza A (H5N1) virus. <i>Lancet Infectious Diseases</i> , The, 2007, 7, 21-31.	9.1	165
78	VII International Symposium on Respiratory Viral Infections. <i>Antiviral Therapy</i> , 2007, 12, 671-693.	1.0	5
79	Spotlight on Respiratory Viruses: Introduction. <i>Antiviral Therapy</i> , 2007, 12, 579-580.	1.0	0
80	Antiviral Resistance in Influenza Viruses – Implications for Management and Pandemic Response. <i>New England Journal of Medicine</i> , 2006, 354, 785-788.	27.0	169
81	Post-Exposure Influenza Prophylaxis with Oseltamivir. <i>Pharmacoeconomics</i> , 2006, 24, 373-386.	3.3	21
82	Detection of Influenza Viruses Resistant to Neuraminidase Inhibitors in Global Surveillance during the First 3 Years of Their Use. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 2395-2402.	3.2	333
83	Respiratory viral threats. <i>Current Opinion in Infectious Diseases</i> , 2006, 19, 169-178.	3.1	58
84	Antivirals for influenza: Historical perspectives and lessons learned. <i>Antiviral Research</i> , 2006, 71, 372-378.	4.1	83
85	Antiviral Management of Seasonal and Pandemic Influenza. <i>Journal of Infectious Diseases</i> , 2006, 194, S119-S126.	4.0	100
86	Antiviral Effects on Influenza Viral Transmission and Pathogenicity: Observations from Household-based Trials. <i>American Journal of Epidemiology</i> , 2006, 165, 212-221.	3.4	130
87	Kinetics of Influenza A Virus Infection in Humans. <i>Journal of Virology</i> , 2006, 80, 7590-7599.	3.4	630
88	Comparative Activities of Oseltamivir and Amantadine in Immunocompetent and Immunocompromised Murine Models of Influenza Virus Infection. <i>Journal of Infectious Diseases</i> , 2006, 193, 765-772.	4.0	54
89	Recovery of Drug-Resistant Influenza Virus from Immunocompromised Patients: A Case Series. <i>Journal of Infectious Diseases</i> , 2006, 193, 760-764.	4.0	253
90	Sialidase Fusion Protein as a Novel Broad-Spectrum Inhibitor of Influenza Virus Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 1470-1479.	3.2	211

#	ARTICLE	IF	CITATIONS
91	Pharmacophore Modeling, Docking, and Principal Component Analysis Based Clustering: A Combined Computer-Assisted Approaches To Identify New Inhibitors of the Human Rhinovirus Coat Protein. Journal of Medicinal Chemistry, 2005, 48, 6250-6260.	6.4	44
92	Susceptibilities of Antiviral-Resistant Influenza Viruses to Novel Neuraminidase Inhibitors. Antimicrobial Agents and Chemotherapy, 2005, 49, 4515-4520.	3.2	197
93	Relationship of Pleconaril Susceptibility and Clinical Outcomes in Treatment of Common Colds Caused by Rhinoviruses. Antimicrobial Agents and Chemotherapy, 2005, 49, 4492-4499.	3.2	94
94	Transmission of Avian Influenza Viruses to and between Humans. Journal of Infectious Diseases, 2005, 192, 1311-1314.	4.0	68
95	Cardiac Findings during Uncomplicated Acute Influenza in Ambulatory Adults. Clinical Infectious Diseases, 2005, 40, 415-422.	5.8	72
96	Avian Influenza A (H5N1) Infection in Humans. New England Journal of Medicine, 2005, 353, 1374-1385.	27.0	1,235
97	Neuraminidase inhibitor susceptibility network position statement: antiviral resistance in influenza A/H5N1 viruses. Antiviral Therapy, 2005, 10, 873-7.	1.0	22
98	Neuraminidase Inhibitor Susceptibility Network Position Statement: Antiviral Resistance in Influenza A/H5N1 Viruses. Antiviral Therapy, 2005, 10, 873-877.	1.0	55
99	Efficacy and Tolerability of the Oral Neuraminidase Inhibitor Peramivir in Experimental Human Influenza: Randomized, Controlled Trials for Prophylaxis and Treatment. Antiviral Therapy, 2005, 10, 901-910.	1.0	99
100	Management of Influenza in Households: A Prospective, Randomized Comparison of Oseltamivir Treatment With or Without Postexposure Prophylaxis. Journal of Infectious Diseases, 2004, 189, 440-449.	4.0	301
101	Pandemic Influenza. Pediatric Infectious Disease Journal, 2004, 23, S262-S269.	2.0	47
102	Rhinovirus and the lower respiratory tract. Reviews in Medical Virology, 2004, 14, 17-31.	8.3	224
103	Neuraminidase inhibitors: assessment of limitations to greater therapeutic use. International Congress Series, 2004, 1263, 29-37.	0.2	1
104	Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet, The, 2004, 364, 759-765.	13.7	735
105	Rhinovirus Infections in Hematopoietic Stem Cell Transplant Recipients with Pneumonia. Clinical Infectious Diseases, 2003, 36, 1139-1143.	5.8	129
106	Phase II, Randomized, Double-Blind, Placebo-Controlled Studies of Rupintrivir Nasal Spray 2-Percent Suspension for Prevention and Treatment of Experimentally Induced Rhinovirus Colds in Healthy Volunteers. Antimicrobial Agents and Chemotherapy, 2003, 47, 3907-3916.	3.2	205
107	Efficacy and Safety of Oral Pleconaril for Treatment of Colds Due to Picornaviruses in Adults: Results of 2 Double-Blind, Randomized, Placebo-Controlled Trials. Clinical Infectious Diseases, 2003, 36, 1523-1532.	5.8	270
108	Impact of Oseltamivir Treatment on Influenza-Related Lower Respiratory Tract Complications and Hospitalizations. Archives of Internal Medicine, 2003, 163, 1667.	3.8	443

#	ARTICLE	IF	CITATIONS
109	Safety and efficacy of nebulized zanamivir in hospitalized patients with serious influenza. <i>Antiviral Therapy</i> , 2003, 8, 183-90.	1.0	36
110	Safety and Efficacy of Nebulized Zanamivir in Hospitalized Patients with Serious Influenza. <i>Antiviral Therapy</i> , 2003, 8, 183-190.	1.0	103
111	In Vitro Characterization of A-315675, a Highly Potent Inhibitor of A and B Strain Influenza Virus Neuraminidases and Influenza Virus Replication. <i>Antimicrobial Agents and Chemotherapy</i> , 2002, 46, 1014-1021.	3.2	110
112	Rhinovirus and Coronavirus Infection—Associated Hospitalizations among Older Adults. <i>Journal of Infectious Diseases</i> , 2002, 185, 1338-1341.	4.0	184
113	Accumulation of Defective Neuraminidase (NA) Genes by Influenza A Viruses in the Presence of NA Inhibitors as a Marker of Reduced Dependence on NA. <i>Journal of Infectious Diseases</i> , 2002, 185, 591-598.	4.0	22
114	Drug resistance and influenza pandemics. <i>Lancet, The</i> , 2002, 359, 1862-1863.	13.7	16
115	Drug resistance and influenza pandemics. <i>Lancet, The</i> , 2002, 360, 1704.	13.7	0
116	Detection of influenza virus resistance to neuraminidase inhibitors by an enzyme inhibition assay. <i>Antiviral Research</i> , 2002, 53, 47-61.	4.1	139
117	Current research on respiratory viral infections: Fourth International Symposium. <i>Antiviral Research</i> , 2002, 55, 227-278.	4.1	43
118	A release-competent influenza A virus mutant lacking the coding capacity for the neuraminidase active site. <i>Journal of General Virology</i> , 2002, 83, 2683-2692.	2.9	40
119	Oral pleconaril treatment of picornavirus-associated viral respiratory illness in adults: efficacy and tolerability in phase II clinical trials. <i>Antiviral Therapy</i> , 2002, 7, 53-65.	1.0	23
120	Oral Pleconaril Treatment of Picornavirus-Associated Viral Respiratory Illness in Adults: Efficacy and Tolerability in Phase II Clinical Trials. <i>Antiviral Therapy</i> , 2002, 7, 53-65.	1.0	60
121	Comparison of the Activities of Zanamivir, Oseltamivir, and RWJ-270201 against Clinical Isolates of Influenza Virus and Neuraminidase Inhibitor-Resistant Variants. <i>Antimicrobial Agents and Chemotherapy</i> , 2001, 45, 3403-3408.	3.2	192
122	Influenza virus neuraminidase inhibitors: clinical aspects. <i>International Congress Series</i> , 2001, 1219, 797-806.	0.2	8
123	Therapeutic options for the management of influenza. <i>Current Opinion in Pharmacology</i> , 2001, 1, 482-490.	3.5	36
124	Clinical features of patients with acute respiratory illness and rhinovirus in their bronchoalveolar lavages. <i>Journal of Clinical Virology</i> , 2001, 21, 9-16.	3.1	68
125	Oral oseltamivir treatment of influenza in children. <i>Pediatric Infectious Disease Journal</i> , 2001, 20, 127-133.	2.0	684
126	Symptom pathogenesis during acute influenza: Interleukin-6 and Other cytokine responses. <i>Journal of Medical Virology</i> , 2001, 64, 262-268.	5.0	320

#	ARTICLE	IF	CITATIONS
127	Position statement: global neuraminidase inhibitor susceptibility network. <i>Antiviral Research</i> , 2001, 49, 147-156.	4.1	142
128	Current research on respiratory viral infections: Third International Symposium. <i>Antiviral Research</i> , 2001, 50, 157-196.	4.1	31
129	Perspectives on antiviral use during pandemic influenza. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2001, 356, 1877-1884.	4.0	95
130	Inhaled Zanamivir for the Prevention of Influenza in Families. <i>New England Journal of Medicine</i> , 2000, 343, 1282-1289.	27.0	351
131	Efficacy and Safety of the Oral Neuraminidase Inhibitor Oseltamivir in Treating Acute Influenza. <i>JAMA - Journal of the American Medical Association</i> , 2000, 283, 1016.	7.4	909
132	Impact of Zanamivir on Antibiotic Use for Respiratory Events Following Acute Influenza in Adolescents and Adults. <i>Archives of Internal Medicine</i> , 2000, 160, 3234.	3.8	96
133	Influenza virus neuraminidase inhibitors. <i>Lancet, The</i> , 2000, 355, 827-835.	13.7	642
134	Influenza virus and rhinovirus-related otitis media: potential for antiviral intervention. <i>Vaccine</i> , 2000, 19, S66-S70.	3.8	25
135	Oral Oseltamivir in Human Experimental Influenza B Infection. <i>Antiviral Therapy</i> , 2000, 5, 205-213.	1.0	81
136	Safety and Efficacy of Intravenous Zanamivir in Preventing Experimental Human Influenza A Virus Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 1999, 43, 1616-1620.	3.2	129
137	Efficacy of Tremacamra, a Soluble Intercellular Adhesion Molecule 1, for Experimental Rhinovirus Infection. <i>JAMA - Journal of the American Medical Association</i> , 1999, 281, 1797.	7.4	180
138	Use of the Oral Neuraminidase Inhibitor Oseltamivir in Experimental Human Influenza. <i>JAMA - Journal of the American Medical Association</i> , 1999, 282, 1240.	7.4	500
139	Use of the Selective Oral Neuraminidase Inhibitor Oseltamivir to Prevent Influenza. <i>New England Journal of Medicine</i> , 1999, 341, 1336-1343.	27.0	477
140	Editorial Response: Rhinovirus Pneumonia: A Clinical Entity?. <i>Clinical Infectious Diseases</i> , 1999, 29, 533-535.	5.8	16
141	Polymerase chain reaction-based detection of rhinovirus, respiratory syncytial virus, and coronavirus in otitis media with effusion. <i>Journal of Pediatrics</i> , 1998, 133, 390-394.	1.8	101
142	Trends in Clinical Practice Rhinoviruses: Important respiratory pathogens. <i>Annals of Medicine</i> , 1998, 30, 529-537.	3.8	66
143	Effect of Rimantadine Treatment on Clinical Manifestations and Otologic Complications in Adults Experimentally Infected with Influenza A (H1N1) Virus. <i>Journal of Infectious Diseases</i> , 1998, 177, 1260-1265.	4.0	49
144	Combined Intranasal Ipratropium Bromide and Oxymetazoline in Experimental Rhinovirus Infection. <i>American Journal of Rhinology & Allergy</i> , 1998, 12, 125-130.	2.2	7

#	ARTICLE	IF	CITATIONS
145	Detection of Rhinovirus, Respiratory Syncytial Virus, and Coronavirus Infections in Acute Otitis Media by Reverse Transcriptase Polymerase Chain Reaction. <i>Pediatrics</i> , 1998, 102, 291-295.	2.1	267
146	Increased Interleukin-6 Levels in Nasal Lavage Samples following Experimental Influenza A Virus Infection. <i>Vaccine Journal</i> , 1998, 5, 604-608.	2.6	78
147	Trends in Clinical Practice Rhinoviruses: Important respiratory pathogens. <i>Annals of Medicine</i> , 1998, 30, 529-537.	3.8	4
148	Efficacy and Safety of the Neuraminidase Inhibitor Zanamivir in the Treatment of Influenzavirus Infections. <i>New England Journal of Medicine</i> , 1997, 337, 874-880.	27.0	746
149	Antivirals for Pandemic Influenza. <i>Journal of Infectious Diseases</i> , 1997, 176, S56-S61.	4.0	43
150	Safety and Efficacy of the Neuraminidase Inhibitor GG167 in Experimental Human Influenza. <i>JAMA - Journal of the American Medical Association</i> , 1996, 275, 295.	7.4	222
151	Prolonged Shedding of Amantadine-Resistant Influenza A Viruses by Immunodeficient Patients: Detection by Polymerase Chain Reaction-Restriction Analysis. <i>Journal of Infectious Diseases</i> , 1995, 172, 1352-1355.	4.0	172
152	Localization of Human Rhinovirus Replication in the Upper Respiratory Tract by In Situ Hybridization. <i>Journal of Infectious Diseases</i> , 1995, 171, 1329-1333.	4.0	154
153	Development of Common Cold Symptoms Following Experimental Rhinovirus Infection is Related to Prior Stressful Life Events. <i>Behavioral Medicine</i> , 1992, 18, 115-120.	1.9	144
154	Clinical and epidemiological importance of influenza a viruses resistant to amantadine and rimantadine. <i>Reviews in Medical Virology</i> , 1992, 2, 89-96.	8.3	67
155	Emergence and Apparent Transmission of Rimantadine-Resistant Influenza A Virus in Families. <i>New England Journal of Medicine</i> , 1989, 321, 1696-1702.	27.0	415
156	Modification of experimental rhinovirus colds by receptor blockade. <i>Antiviral Research</i> , 1988, 9, 233-247.	4.1	71
157	Rimantadine Hydrochloride and Amantadine Hydrochloride Use in Influenza A Virus Infections. <i>Infectious Disease Clinics of North America</i> , 1987, 1, 459-478.	5.1	103
158	Combinations of antiviral agents for treatment of influenza virus infections. <i>Journal of Antimicrobial Chemotherapy</i> , 1986, 18, 177-183.	3.0	33
159	Prevention of Natural Colds by Contact Prophylaxis with Intranasal Alpha ₂ -Interferon. <i>New England Journal of Medicine</i> , 1986, 314, 71-75.	27.0	206
160	Immune response of adults to sequential influenza vaccination. <i>Journal of Medical Virology</i> , 1984, 14, 169-175.	5.0	36
161	Comparative therapeutic effect of aerosolized and oral rimantadine HC1 in experimental human influenza A virus infection. <i>Antiviral Research</i> , 1982, 2, 147-153.	4.1	26
162	Zoonotic Paramyxoviruses. , 0, , 949-966.		2

#	ARTICLE	IF	CITATIONS
163	Filoviruses. , 0 , 981-1007.		1